Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy

An analysis based on the CURVES study

Daniel E. Hilleman, Susan M. Heineman, Pamela A. Foral

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We conducted a post hoc pharmacoeconomic analysis of a multicenter, open-label, randomized, parallel-group, 8-week efficacy-safety comparison of five HMG-CoA reductase inhibitors - atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin. The 534 patients requiring cholesterol-lowering therapy took the drugs for 8 weeks with 15 different regimens. Low-density lipoprotein (LDL) was measured after 6 weeks of diet (baseline) and after 8 weeks of treatment with a study drug. At dosages of 10, 20, and 40 mg/day, atorvastatin was associated with significantly greater reductions in LDL than equivalent dosages of the other agents. Cost-effectiveness calculated as the annual acquisition cost/percentage LDL reduction was greatest with atorvastatin 10 mg ($17.96), fluvastatin 40 mg ($19.83), atorvastatin 20 mg ($22.85), and atorvastatin 40 mg ($24.96). All other dosages were above $25.00/year/percentage LDL reduction. Atorvastatin was the most cost- effective HMG-CoA reductase inhibitor. Fluvastatin 40 mg/day also had a favorable cost:effectiveness ratio but lowered LDL only by 23%.

Original languageEnglish
Pages (from-to)819-822
Number of pages4
JournalPharmacotherapy
Volume20
Issue number7 I
StatePublished - 2000

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmaceutical Economics
fluvastatin
LDL Lipoproteins
Cost-Benefit Analysis
Therapeutics
Costs and Cost Analysis
Pravastatin
Lovastatin
Simvastatin
Atorvastatin Calcium
Cholesterol
Diet
Safety
Drug Therapy
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy : An analysis based on the CURVES study. / Hilleman, Daniel E.; Heineman, Susan M.; Foral, Pamela A.

In: Pharmacotherapy, Vol. 20, No. 7 I, 2000, p. 819-822.

Research output: Contribution to journalArticle

@article{44f4c1af91994aac95716978f48d77d8,
title = "Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: An analysis based on the CURVES study",
abstract = "We conducted a post hoc pharmacoeconomic analysis of a multicenter, open-label, randomized, parallel-group, 8-week efficacy-safety comparison of five HMG-CoA reductase inhibitors - atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin. The 534 patients requiring cholesterol-lowering therapy took the drugs for 8 weeks with 15 different regimens. Low-density lipoprotein (LDL) was measured after 6 weeks of diet (baseline) and after 8 weeks of treatment with a study drug. At dosages of 10, 20, and 40 mg/day, atorvastatin was associated with significantly greater reductions in LDL than equivalent dosages of the other agents. Cost-effectiveness calculated as the annual acquisition cost/percentage LDL reduction was greatest with atorvastatin 10 mg ($17.96), fluvastatin 40 mg ($19.83), atorvastatin 20 mg ($22.85), and atorvastatin 40 mg ($24.96). All other dosages were above $25.00/year/percentage LDL reduction. Atorvastatin was the most cost- effective HMG-CoA reductase inhibitor. Fluvastatin 40 mg/day also had a favorable cost:effectiveness ratio but lowered LDL only by 23{\%}.",
author = "Hilleman, {Daniel E.} and Heineman, {Susan M.} and Foral, {Pamela A.}",
year = "2000",
language = "English",
volume = "20",
pages = "819--822",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "7 I",

}

TY - JOUR

T1 - Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy

T2 - An analysis based on the CURVES study

AU - Hilleman, Daniel E.

AU - Heineman, Susan M.

AU - Foral, Pamela A.

PY - 2000

Y1 - 2000

N2 - We conducted a post hoc pharmacoeconomic analysis of a multicenter, open-label, randomized, parallel-group, 8-week efficacy-safety comparison of five HMG-CoA reductase inhibitors - atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin. The 534 patients requiring cholesterol-lowering therapy took the drugs for 8 weeks with 15 different regimens. Low-density lipoprotein (LDL) was measured after 6 weeks of diet (baseline) and after 8 weeks of treatment with a study drug. At dosages of 10, 20, and 40 mg/day, atorvastatin was associated with significantly greater reductions in LDL than equivalent dosages of the other agents. Cost-effectiveness calculated as the annual acquisition cost/percentage LDL reduction was greatest with atorvastatin 10 mg ($17.96), fluvastatin 40 mg ($19.83), atorvastatin 20 mg ($22.85), and atorvastatin 40 mg ($24.96). All other dosages were above $25.00/year/percentage LDL reduction. Atorvastatin was the most cost- effective HMG-CoA reductase inhibitor. Fluvastatin 40 mg/day also had a favorable cost:effectiveness ratio but lowered LDL only by 23%.

AB - We conducted a post hoc pharmacoeconomic analysis of a multicenter, open-label, randomized, parallel-group, 8-week efficacy-safety comparison of five HMG-CoA reductase inhibitors - atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin. The 534 patients requiring cholesterol-lowering therapy took the drugs for 8 weeks with 15 different regimens. Low-density lipoprotein (LDL) was measured after 6 weeks of diet (baseline) and after 8 weeks of treatment with a study drug. At dosages of 10, 20, and 40 mg/day, atorvastatin was associated with significantly greater reductions in LDL than equivalent dosages of the other agents. Cost-effectiveness calculated as the annual acquisition cost/percentage LDL reduction was greatest with atorvastatin 10 mg ($17.96), fluvastatin 40 mg ($19.83), atorvastatin 20 mg ($22.85), and atorvastatin 40 mg ($24.96). All other dosages were above $25.00/year/percentage LDL reduction. Atorvastatin was the most cost- effective HMG-CoA reductase inhibitor. Fluvastatin 40 mg/day also had a favorable cost:effectiveness ratio but lowered LDL only by 23%.

UR - http://www.scopus.com/inward/record.url?scp=0033945012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033945012&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 819

EP - 822

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 7 I

ER -